Breast Cancer Clinical Trial

Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer

Summary

The purpose of the study is to determine the feasibility of genomically guided radiation therapy (RT) in people with triple negative (HER2 negative, hormone receptor negative) breast cancer undergoing breast conservation therapy.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Participants should have undergone breast conservation therapy with a lumpectomy and axillary evaluation to consist of a sentinel node biopsy or axillary dissection
Confirmation of Triple Negative (TN) breast cancer by tissue biopsy
Life expectancy >16 weeks
KPS ≥ 70
Age ≥ 18 years
Participants with surgery within 14 days should have recovered from all effects of the surgery and be cleared by their surgeon
There is no limit on prior systemic therapies
Women of childbearing potential and sexually active males must commit to the use of effective contraception while on study
Ability to sign an informed consent form, which can be signed by a family member or health care proxy. Informed consent must be given before study enrollment

Exclusion Criteria:

Major surgery or significant traumatic injury that has not been recovered from 14 days before study initiation
Women who are pregnant or breastfeeding
Positive surgical margins
History of allergy or hypersensitivity to any of the study drugs or study drug components
Metastatic breast cancer

Study is for people with:

Breast Cancer

Phase:

Phase 2

Estimated Enrollment:

86

Study ID:

NCT05528133

Recruitment Status:

Recruiting

Sponsor:

H. Lee Moffitt Cancer Center and Research Institute

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Moffitt Cancer Center
Tampa Florida, 33612, United States More Info
Michelle DeJesus
Contact
813-745-6911
[email protected]
Kamran Ahmed, MD
Principal Investigator
Roberto Diaz, MD, PhD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 2

Estimated Enrollment:

86

Study ID:

NCT05528133

Recruitment Status:

Recruiting

Sponsor:


H. Lee Moffitt Cancer Center and Research Institute

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.